Study Condition(s): Small Cell Lung Cancer

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

Study Alias: JZHB

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT03898791 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria

Gender

Male Female

Age

18+ years

Time Commitment

Your participation in this trial could last up to 20 months, depending on how you and your tumor respond.

Inclusion Criteria: -Participants must have histological or cytological evidence of a diagnosis of platinum sensitive small cell lung cancer that is extensive stage -Participants must have adequate organ function -Participants must have a performance status (PS) of ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale -Participants must have discontinued previous treatments for cancer. -Participants must be able to swallow capsules

Exclusion Criteria: -Participants must not be currently enrolled in a clinical study -Participants must not have a serious concomitant systemic disorder -Participants must not have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C -Participants must not have a significant cardiac condition -Participants must not have previously received an aurora kinase inhibitor

Where to Participate

0 locations are currently available of 35 planned
Invalid Postal Code.
Please re-enter postal code.
Alert Me Icon Sign up for email alerts about new Lilly trials and locations.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}
Alert Me Icon Sign up for email alerts about new Lilly trials and locations.

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.